117 related articles for article (PubMed ID: 32588421)
21. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.
Stulak JM; Deo S; Schirger J; Aaronson KD; Park SJ; Joyce LD; Daly RC; Pagani FD
Ann Thorac Surg; 2013 Dec; 96(6):2161-7. PubMed ID: 24035302
[TBL] [Abstract][Full Text] [Related]
22. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT
Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489
[TBL] [Abstract][Full Text] [Related]
23. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
[TBL] [Abstract][Full Text] [Related]
24. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
Gupta DK; Giugliano RP; Ruff CT; Claggett B; Murphy S; Antman E; Mercuri MF; Braunwald E; Solomon SD;
J Am Soc Echocardiogr; 2016 Jun; 29(6):537-44. PubMed ID: 27106009
[TBL] [Abstract][Full Text] [Related]
26. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
[TBL] [Abstract][Full Text] [Related]
27. Thromboembolic and haemorrhagic events in patients with atrial fibrillation: a prospective cohort study in UK primary and secondary care.
Robson J; Mathur R; Priebe M; Ahmed Z; Ayerbe L
Br J Gen Pract; 2019 Jun; 69(683):e407-e412. PubMed ID: 31015222
[TBL] [Abstract][Full Text] [Related]
28. Female Sex as a Risk Factor for Ischemic Stroke and Systemic Embolism in Chinese Patients With Atrial Fibrillation: A Report From the China-AF Study.
Lan DH; Jiang C; Du X; He L; Guo XY; Zuo S; Xia SJ; Chang SS; Wen SN; Wu JH; Ruan YF; Long DY; Tang RB; Yu RH; Sang CH; Bai R; Liu N; Jiang CX; Li SN; Dong JZ; Lip GYH; Chen AH; Ma CS
J Am Heart Assoc; 2018 Oct; 7(19):e009391. PubMed ID: 30371338
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Raña-Míguez P; Anguita M; Muñiz J; Cequier Á; Bertomeu-Martínez V; Valdés M; Vicente V; Lip GYH; Roldán V
Am J Cardiol; 2017 Dec; 120(12):2176-2181. PubMed ID: 29111209
[TBL] [Abstract][Full Text] [Related]
30. Risk of arterial thromboembolism, bleeding and mortality in atrial fibrillation patients with comorbid cancer: A systematic review and meta-analysis.
Balomenakis C; Papazoglou AS; Vlachopoulou D; Kartas A; Moysidis DV; Vouloagkas I; Tsagkaris C; Georgopoulos K; Samaras A; Karagiannidis E; Giannakoulas G
Hellenic J Cardiol; 2023; 74():65-73. PubMed ID: 37414144
[TBL] [Abstract][Full Text] [Related]
31. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
32. Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease-findings from the SAKURA AF Registry.
Fukamachi D; Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Nishida T; Kojima T; Hanada S; Nomoto K; Sonoda K; Arima K; Kogawa R; Takahashi F; Kotani T; Ohkubo K; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Curr Med Res Opin; 2019 Dec; 35(12):2053-2062. PubMed ID: 31355684
[No Abstract] [Full Text] [Related]
33. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
[TBL] [Abstract][Full Text] [Related]
34. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
35. Body mass index and adverse events in patients with incident atrial fibrillation.
Overvad TF; Rasmussen LH; Skjøth F; Overvad K; Lip GY; Larsen TB
Am J Med; 2013 Jul; 126(7):640.e9-17. PubMed ID: 23601271
[TBL] [Abstract][Full Text] [Related]
36. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
Pastori D; Nocella C; Farcomeni A; Bartimoccia S; Santulli M; Vasaturo F; Carnevale R; Menichelli D; Violi F; Pignatelli P;
J Am Coll Cardiol; 2017 Sep; 70(12):1455-1462. PubMed ID: 28911508
[TBL] [Abstract][Full Text] [Related]
37. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.
Martinez C; Wallenhorst C; Rietbrock S; Freedman B
J Am Heart Assoc; 2020 Jan; 9(2):e014376. PubMed ID: 31937194
[TBL] [Abstract][Full Text] [Related]
38. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
Int J Cardiol; 2013 Sep; 167(6):2682-7. PubMed ID: 22795403
[TBL] [Abstract][Full Text] [Related]
39. Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events.
Carnevale R; Nocella C; Pignatelli P; Bartimoccia S; Stefanini L; Basili S; Novo M; D'Amico A; Cammisotto V; Pastori D; Violi F
Atherosclerosis; 2018 Jul; 274():29-34. PubMed ID: 29747088
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
